Sensei Biotherapeutics Announces Board and Officer Changes
Ticker: SNSE · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $425,000, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, officer-appointment
TL;DR
Sensei Biotherapeutics reshuffled its board and exec team on 12/22/25.
AI Summary
Sensei Biotherapeutics, Inc. announced on December 22, 2025, changes in its board of directors and officer appointments. Specifically, the company reported the departure of certain directors and officers, along with the election of new directors and the appointment of new officers. The filing also touches upon compensatory arrangements for certain officers.
Why It Matters
Changes in leadership and board composition can signal shifts in company strategy, governance, or financial direction.
Risk Assessment
Risk Level: medium — Changes in directors and officers can indicate internal shifts that may impact future performance or strategy.
Key Numbers
- 001-39980 — SEC File Number (Identifies the company's filing with the SEC.)
- 20850 — ZIP Code (Part of the company's principal executive office address.)
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- December 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
Who departed from Sensei Biotherapeutics, Inc. on or before December 22, 2025?
The filing indicates the departure of directors or certain officers, but does not name specific individuals in this section.
Were new directors elected by Sensei Biotherapeutics, Inc. as of December 22, 2025?
Yes, the filing states that new directors were elected as part of the reported events on December 22, 2025.
What is the principal executive office address for Sensei Biotherapeutics, Inc.?
The principal executive office is located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated December 22, 2025.
Does this filing include information on officer compensation arrangements?
Yes, the filing notes 'Compensatory Arrangements of Certain Officers' as an item of information.
Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2025-12-23 17:00:23
Key Financial Figures
- $425,000 — s for Messrs. Gerry and Craver would be $425,000 and $400,000, respectively, each effect
- $400,000 — Gerry and Craver would be $425,000 and $400,000, respectively, each effective as of Nov
Filing Documents
- d68669d8k.htm (8-K) — 25KB
- 0001193125-25-331113.txt ( ) — 140KB
- snse-20251222.xsd (EX-101.SCH) — 3KB
- snse-20251222_lab.xml (EX-101.LAB) — 18KB
- snse-20251222_pre.xml (EX-101.PRE) — 11KB
- d68669d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: December 23, 2025 /s/ Christopher W. Gerry Christopher W. Gerry President and Principal Executive Officer 3